[go: up one dir, main page]

DE60305113D1 - Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung - Google Patents

Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung

Info

Publication number
DE60305113D1
DE60305113D1 DE60305113T DE60305113T DE60305113D1 DE 60305113 D1 DE60305113 D1 DE 60305113D1 DE 60305113 T DE60305113 T DE 60305113T DE 60305113 T DE60305113 T DE 60305113T DE 60305113 D1 DE60305113 D1 DE 60305113D1
Authority
DE
Germany
Prior art keywords
drugs
provision
boric acid
acid salts
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60305113T
Other languages
English (en)
Other versions
DE60305113T2 (de
Inventor
David Jonathan Madge
Mark Dolman
Sophie Marie Combe-Marzelle
John Joseph Deadman
Anthony James Kennedy
Sanjay Kumar Kakkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trigen Ltd
Original Assignee
Trigen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220822A external-priority patent/GB0220822D0/en
Priority claimed from GB0220764A external-priority patent/GB0220764D0/en
Priority claimed from GB0307817A external-priority patent/GB0307817D0/en
Priority claimed from GB0311237A external-priority patent/GB0311237D0/en
Priority claimed from GB0315691A external-priority patent/GB0315691D0/en
Application filed by Trigen Ltd filed Critical Trigen Ltd
Publication of DE60305113D1 publication Critical patent/DE60305113D1/de
Application granted granted Critical
Publication of DE60305113T2 publication Critical patent/DE60305113T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60305113T 2002-09-09 2003-09-09 Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung Expired - Lifetime DE60305113T2 (de)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB0220822A GB0220822D0 (en) 2002-09-09 2002-09-09 Boropeptides
GB0220822 2002-09-09
GB0220764A GB0220764D0 (en) 2002-09-09 2002-09-09 Boropeptides
GB0220764 2002-09-09
GB0307817A GB0307817D0 (en) 2003-04-04 2003-04-04 Boronic acid compounds
GB0307817 2003-04-04
GB0311237 2003-05-16
GB0311237A GB0311237D0 (en) 2003-05-16 2003-05-16 Boronic acid compounds
GB0315691A GB0315691D0 (en) 2003-07-04 2003-07-04 Boropeptides
GB0315691 2003-07-04
US48578603P 2003-07-08 2003-07-08
US485786P 2003-07-08

Publications (2)

Publication Number Publication Date
DE60305113D1 true DE60305113D1 (de) 2006-06-14
DE60305113T2 DE60305113T2 (de) 2006-12-07

Family

ID=31721886

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60305113T Expired - Lifetime DE60305113T2 (de) 2002-09-09 2003-09-09 Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung
DE60317039T Expired - Lifetime DE60317039T2 (de) 2002-09-09 2003-09-09 Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben
DE60304956T Expired - Lifetime DE60304956T2 (de) 2002-09-09 2003-09-09 In parenteralen Formulierungen für die selektive Thrombininhibierung verwendbare Borsäuresalze

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE60317039T Expired - Lifetime DE60317039T2 (de) 2002-09-09 2003-09-09 Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben
DE60304956T Expired - Lifetime DE60304956T2 (de) 2002-09-09 2003-09-09 In parenteralen Formulierungen für die selektive Thrombininhibierung verwendbare Borsäuresalze

Country Status (20)

Country Link
EP (8) EP1396270B1 (de)
JP (3) JP2006509034A (de)
KR (2) KR20050057294A (de)
CN (2) CN100447151C (de)
AT (3) ATE376551T1 (de)
AU (3) AU2003263328A1 (de)
BR (1) BR0314450A (de)
CA (3) CA2535788A1 (de)
CY (1) CY1105381T1 (de)
DE (3) DE60305113T2 (de)
DK (2) DK1396270T3 (de)
ES (2) ES2264515T3 (de)
HK (1) HK1063154A1 (de)
IL (1) IL167294A (de)
MX (2) MXPA05002662A (de)
NZ (2) NZ539333A (de)
PL (2) PL376535A1 (de)
PT (1) PT1396270E (de)
SI (2) SI1400245T1 (de)
WO (3) WO2004022072A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405280D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405267D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006059082A1 (en) * 2004-11-30 2006-06-08 Trigen Limited Oxidised lipids as reversal agents for boronic acid drugs
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
US7261742B2 (en) 2005-10-13 2007-08-28 S.C. Johnson & Son, Inc. Method of deodorizing a textile
KR20100066515A (ko) * 2007-08-21 2010-06-17 알자 코퍼레이션 보론산 화합물의 리포좀 제제
AU2008288917A1 (en) * 2007-08-21 2009-02-26 Alza Corporation Liposome compositions for in vivo administration of boronic acid compounds
US8389232B2 (en) * 2008-05-13 2013-03-05 The Regents Of The University Of California Fluorescence detection of poison oak oil
PL2318419T3 (pl) 2008-06-17 2015-08-31 Millennium Pharm Inc Związki estrów boronianowych i ich kompozycje farmaceutyczne
US20120059036A1 (en) * 2008-11-21 2012-03-08 Marco Valgimigli Method for reducing thrombocytopenia and thrombocytopenia-associated mortality
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
CN101928329B (zh) * 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
WO2013112881A1 (en) 2012-01-27 2013-08-01 Thomas Jefferson University Mct protein inhibitor-related prognostic and therapeutic methods
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
CA2963203A1 (en) * 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
UA124672C2 (uk) 2016-06-21 2021-10-27 Оріон Офтальмолоджі Ллс Гетероциклічні похідні пролінаміду
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
CN109187155B (zh) * 2018-07-27 2021-08-13 临沂大学 一种水样中有效硼的提取纯化方法和一种硼同位素组成的测试方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN113121666B (zh) * 2021-03-10 2023-09-12 厦门大学 抗菌肽Scybaumancin105-127及其应用
CN114106346B (zh) * 2021-10-29 2023-04-18 重庆第二师范学院 一种稀土双金属电致化学发光材料及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5856695A (ja) 1981-09-28 1983-04-04 Nitto Boseki Co Ltd 新規なトロンビン測定用基質
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5574014A (en) 1988-04-28 1996-11-12 Thrombosis Research Institute Inhibitors of trypsin-like enzymes
EP0341661A3 (de) 1988-05-11 1991-05-02 The Du Pont Merck Pharmaceutical Company Alpha-Aminoborsäure-Derivate enthaltende Peptid-Mittel Zusammensetzungen
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
US5648338A (en) 1990-11-06 1997-07-15 Thrombosis Research Institute Inhibitors and substrates of thrombin
CA2109526C (en) 1991-04-30 1998-01-20 Dwight M. Peterson Liquid detergents with an aryl boroic acid
GB9224702D0 (en) 1992-11-25 1993-01-13 Thrombosis Res Inst Boronic ester synthesis
FR2701951B1 (fr) * 1993-02-24 1995-06-09 Adir Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH08507501A (ja) 1993-03-03 1996-08-13 サンド・リミテッド プロテアーゼ阻害活性を有するペプチドボロン酸誘導体
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
AU6448794A (en) * 1993-03-24 1994-10-11 Du Pont Merck Pharmaceutical Company, The Boronic acid and ester inhibitors of thrombin
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
SE9900043D0 (sv) 1999-01-11 1999-01-11 Astra Ab New use
US5681978A (en) * 1993-07-07 1997-10-28 Washington State University Research Foundation Method for the stereocontrolled synthesis of stegobinone and useful borane intermediates
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
AU7922794A (en) * 1993-10-07 1995-05-01 Du Pont Merck Pharmaceutical Company, The Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US5462964A (en) * 1993-10-20 1995-10-31 The Du Pont Merck Pharmaceutical Company Dipeptide boronic acid inhibitors of trypsin-like enzymes
US5431842A (en) 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
FR2721611B1 (fr) 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
GB9502985D0 (en) 1995-02-16 1995-04-05 Thrombosis Res Inst Enzyme inhibitors
GB9515489D0 (en) 1995-07-28 1995-09-27 Sandoz Ltd Organic compounds
GB9613718D0 (en) * 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
GB9724786D0 (en) * 1997-11-25 1998-01-21 Danbiosyst Uk Oral delivery system
EP1196436A2 (de) 1999-07-07 2002-04-17 Bristol-Myers Squibb Pharma Company Peptidboronsäure inhibitore des hepatitis c virus proteases
SE9904483D0 (sv) 1999-12-08 1999-12-08 Astra Ab New use
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
PT3078667T (pt) * 2001-01-25 2018-12-28 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulação de compostos de ácido borónico
DE10133786A1 (de) 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

Also Published As

Publication number Publication date
EP1695711A3 (de) 2008-01-02
CA2535788A1 (en) 2004-03-18
MXPA05002661A (es) 2005-08-19
ATE376551T1 (de) 2007-11-15
SI1396270T1 (sl) 2006-10-31
CN1684693A (zh) 2005-10-19
PT1396270E (pt) 2006-08-31
CN100447151C (zh) 2008-12-31
BR0314450A (pt) 2005-07-26
NZ539333A (en) 2007-02-23
EP1695712A2 (de) 2006-08-30
CA2535792A1 (en) 2004-03-18
MXPA05002662A (es) 2005-09-20
EP1400245A1 (de) 2004-03-24
EP1561466A3 (de) 2006-08-23
ES2263924T3 (es) 2006-12-16
KR20050057295A (ko) 2005-06-16
EP1466916B1 (de) 2007-10-24
ATE324899T1 (de) 2006-06-15
AU2003263328A1 (en) 2004-03-29
EP1466916A1 (de) 2004-10-13
EP1396270B1 (de) 2006-05-10
DE60304956D1 (de) 2006-06-08
DE60305113T2 (de) 2006-12-07
JP2006511593A (ja) 2006-04-06
WO2004022072A1 (en) 2004-03-18
DE60317039D1 (de) 2007-12-06
EP1695711A2 (de) 2006-08-30
WO2004022071A1 (en) 2004-03-18
ATE325611T1 (de) 2006-06-15
EP1695712A3 (de) 2008-01-09
AU2003263343A1 (en) 2004-03-29
DK1396270T3 (da) 2006-08-28
EP1466917A1 (de) 2004-10-13
JP2006503903A (ja) 2006-02-02
EP1561466A2 (de) 2005-08-10
HK1063154A1 (en) 2004-12-17
DK1400245T3 (da) 2006-08-28
CN1681517A (zh) 2005-10-12
PL376439A1 (en) 2005-12-27
DE60317039T2 (de) 2008-07-31
CY1105381T1 (el) 2010-07-28
EP1396269A1 (de) 2004-03-10
WO2004022070A1 (en) 2004-03-18
KR20050057294A (ko) 2005-06-16
AU2003263333A1 (en) 2004-03-29
CN100553639C (zh) 2009-10-28
JP2006509034A (ja) 2006-03-16
IL167294A (en) 2008-11-03
CA2536010A1 (en) 2004-03-18
SI1400245T1 (sl) 2006-10-31
PL376535A1 (pl) 2006-01-09
ES2264515T3 (es) 2007-01-01
DE60304956T2 (de) 2007-01-25
EP1396270A1 (de) 2004-03-10
EP1400245B1 (de) 2006-05-03
NZ539334A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
DE60305113D1 (de) Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung
TR199500826A2 (tr) Multipl ünite tablet doz formu 2.
EP1708686A4 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
RS51764B (en) TRANSDERMAL PHARMACEUTICAL COMPOSITION
SE0102057D0 (sv) New Salts I
SE0102058D0 (sv) New Salts II
PA8503701A1 (es) Agentes terapeuticos
ATE241640T1 (de) Fusidinsäure-derivate
DE50212538D1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten
AU2003298203A1 (en) Medicaments containing substituted 2,5-diaminomethyl-1h-pyrroles

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KOENIG SZYNKA TILMANN VON RENESSE, 40549 DUESSELDO